Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Leptospirosis: clinical aspects

Senaka Rajapakse
Download PDF
DOI: https://doi.org/10.7861/clinmed.2021-0784
Clin Med January 2022
Senaka Rajapakse
AUniversity of Colombo, Colombo, Sri Lanka
Roles: professor in clinical medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: senaka@med.cmb.ac.lk
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

Leptospirosis is one of the most important zoonotic bacterial diseases worldwide, commonly affecting resource-poor populations and resulting in significant morbidity and mortality. This article provides an overview of the epidemiology, clinical manifestations, diagnosis and treatment of human leptospirosis.

KEYWORDS:
  • leptospirosis
  • Leptospira
  • acute febrile illness
  • jaundice
  • pulmonary haemorrhage

Key points

  • Leptospirosis is a zoonosis which is highly prevalent in the tropics. Transmission is primarily through occupational exposure to rodents and other animals, although recreational exposure is also known to occur.

  • Acute kidney injury, hepatic derangement, myocardial involvement and pulmonary haemorrhage are serious complications, and a myriad of other manifestations have been reported.

  • Diagnosis of leptospirosis is based on characteristic clinical features occurring with a history of risk exposure, together with laboratory confirmation through serology or detection of the organism or its DNA.

  • Antibiotics and supportive therapy are the mainstay of management. No other specific evidence-based therapies exist at present.

  • No effective vaccine is currently available, and prevention is through avoidance of risk exposure, with a degree of protection provided by chemoprophylaxis.

Introduction

Leptospirosis is one of the most important zoonotic bacterial infections worldwide.1,2 It most commonly affects resource-poor populations, resulting in significant morbidity and many deaths. The infection is estimated to cause one million cases and around 58,900 deaths annually, with a case fatality ratio of 6.85%.3

History

Adolph Weil first described leptospirosis in 1886 as a febrile illness with icterus, enlarged spleen, renal failure and conjunctivitis associated with outdoor occupations where people came into contact with water.4 Thus, the severe form was named ‘Weil's disease’. There are several descriptions reported much earlier in ancient texts that match the clinical features of leptospirosis: ‘cane-cutter's disease’ or ‘swine-herd's disease’ in Europe, ‘rice field jaundice’ in ancient Chinese texts, and ‘Akiyami (autumn fever)’ in Japan. The causative organism was first described in 1907 by Stimson, who demonstrated the presence of spirochaetes in the kidneys of a patient dying of the disease; the organism was named Spirochaeta interrogans because of the question-mark shape of the organism.1

Taxonomy and classification

Leptospirae are free-living aerobic spirochaetes with characteristic hooked ends, 6-20 μm in length, with an approximate diameter of 0.1 μm. The surface structures of leptospirae are composed of a cytoplasmic membrane and a peptidoglycan outer cell wall, and an outer membrane sheath composed of a lipid bilayer,5 thus showing features of both gram-negative and gram-positive bacteria. The organisms are motile, by means of endoflagellae.

Only certain strains cause disease in mammalian hosts. The taxonomy is complex.6 Traditionally, the genus Leptospira was divided into two species: L interrogans (all the pathogenic strains) and L biflexa (all the saprophytic strains). Currently, leptospira are classified according to genotypes, and according to serovars. There are 21 species based on genotypic classification, nine of which are pathogenic, and five intermediate, the rest being non-pathogenic strains. Most of the pathogenic strains are classified under the L interrogans block. Serovars and serogroups are classified based on serological testing, and not DNA. Around 240 serovars have been identified, and these are grouped into several serogroups. Only a few of these are pathogenic. Strains with similar DNA can appear in different serogroups, and serovars belonging to the same serogroup can be genetically diverse. In the currently accepted taxonomy, the nomenclature is as follows: ‘Genus species serovar Serovar name’ - for example, Leptopira interrogans serovar Ballum.

Epidemiology and transmission

Leptospirosis is highly prevalent in the tropics, with 73% of cases occurring in this zone, in particular in South-East Asia, East Sub-Saharan Africa, the Caribbean and Oceania. It is common among the rural farming populations and impoverished urban and semi-urban populations, particularly affecting young male adults. Farmers, those in contact with livestock, those exposed to rodents at their workplace, and people living in areas where sanitation is poor are at highest risk.3 Recreational exposure in those undertaking water sports has also been described.7 Urban outbreaks are common in settings where sanitation is poor, and rats breed in abundance.8 Incidence rates have generally been stable globally; however, numerous large outbreaks have occurred from time to time in certain countries, in some instances related to natural disasters associated with flooding.3

Nearly all mammals can serve as carriers of leptospirosis, harbouring and shedding the organisms from the proximal tubules of the kidneys.2 The rat is by far the most important carrier responsible for human leptospirosis. This is because of the ubiquitous presence of rats in the proximity of human habitats, and because rats excrete very high concentrations of organisms, even several months after initial infection. The commonest means of transmission to humans is through abrasions on the skin and mucous membranes coming into contact with water contaminated with infected rat urine. Humans are incidental hosts, and are at greater risk when working or living in environments in proximity with the maintenance hosts, especially rats and farm animals.

Effective control of leptospirosis is difficult because of two epidemiological features of the disease. Firstly, leptospira are capable of developing a symbiotic relationship with many animal hosts, where the organisms persist in the renal tubules for long periods, with shedding of the bacteria in the urine, without causing disease to the host. Secondly, wild animals provide an important reservoir, continuously re-infecting domestic animals.

Clinical manifestations

Human leptospirosis has diverse clinical manifestations. Clinical illness in humans can range from a mild, self-limiting acute febrile illness to a severe, life-threatening condition with multiple organ dysfunction.1,2 Many organ systems can be involved, to varying degrees, and an array of atypical or unusual manifestations and complications have also been described. The clinical features of leptospirosis are similar to those seen in many other febrile illnesses, especially diseases seen in the tropics, such as dengue and other haemorrhagic fevers, rickettsial infection, malaria, and bacterial sepsis. While the majority present with uncomplicated fever, approximately 10% develop severe disease.2,9 The classical presentation with conjunctival suffusion, jaundice, and acute kidney injury constitutes Weil's syndrome.2 Pulmonary haemorrhage has recently been shown to be an important cause of mortality.2,10

The incubation period shows wide variation, from 2-20 days, usually 7-12 days. A biphasic illness is seen in some patients. The clinical course of leptospirosis has been classically divided into a ‘leptospiraemic phase’ or acute phase, followed by an ‘immune phase’.11 The initial ‘leptospiraemic phase’ is said to last for three to nine days, and presents as a non-specific acute febrile illness. Fever, chills, myalgia and headache are present. Conjunctival suffusion is a characteristic finding, developing on the third to fourth day. Myalgia can be severe, and can usually involves the calf, abdomen (mimicking acute abdomen) and paraspinal muscles (resulting in meningism). The ‘leptospiraemic’ or ‘septicaemic’ phase is followed by an immune phase, where IgM antibodies appear in the blood, and organisms are excreted in the urine. Presumably, the organisms settle in higher concentrations in the proximal tubules of the kidney (and other organs) during this phase. Depending on the degree of organ involvement and the virulence of the organism, serious manifestations occur during this stage. In practice, this differentiation into phases is arbitrary, and while there can be a brief period of defervescence between these phases, there often is overlap between them. While recovery takes place in the majority of patients, in a small number of infected individuals there is persistent high fever, with the development of jaundice, acute kidney injury and other serious organ dysfunction.

The pathogenesis of severe leptospirosis is poorly understood; however, it is thought to be due to a form of vasculitis. As with other bacterial infections, both direct damage to tissues by leptospira and immune-mediated mechanisms are responsible for tissue and organ damage, deranged tissue microcirculation and endothelial dysfunction. Although jaundice is a prominent feature, death often results from complications of acute kidney injury, myocardial involvement or pulmonary haemorrhage. Pulmonary involvement, in extreme forms with pulmonary haemorrhage, other haemorrhagic manifestations, and myocarditis are important, serious manifestations resulting in high mortality. A myriad of atypical or unusual manifestations have been reported with human leptospirosis, including nervous system involvement (acute disseminated encephalomyelitis, hydrocephalus and raised intracranial pressure, encephalitis-induced coma, intracranial vascular events; intracranial bleeding and thrombosis, cerebellar syndrome, transverse myelitis, Guillain-Barré syndrome, mononeuritis and mononeuritis multiplex including cranial nerve palsies), ocular manifestations (uveitis, optic neuritis, retinal phlebitis), haematological involvement (pancytopaenia, haemolytic anaemia, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura) and gastrointestinal involvement (pancreatitis, cholecystitis).12

Diagnosis

Diagnosis of leptospirosis is made largely on the presence of suggestive clinical features, with a history of risk exposure. Leptospirosis should be suspected in any patient with a history of risk exposure, and any of the following: headache, myalgia, prostration, jaundice, conjunctival suffusion, oliguria, features of meningeal irritation, haemorrhage, features of cardiac failure or arrhythmia, cough, breathlessness, skin rash, or any other evidence of organ involvement or dysfunction (Box 1).

View this table:
  • View inline
  • View popup
Box 1.

Features of organ involvement in leptospirosis

Many diagnostic tests are available for leptospirosis, but the availability of such tests in resource-poor settings is limited. Diagnostic accuracy is also variable, especially for serological tests. The cut-off values for seropositivity in a single sample are likely to depend on the regional seroprevalence. Cross-reactivity with other infections can further confound the results.

Broadly, the diagnostic tests are divided into those which provide direct evidence of infection (demonstration of leptospires or its DNA, or culture) and tests providing indirect evidence of infection (demonstration of antibodies to leptospirosis) (Box 2).

View this table:
  • View inline
  • View popup
Box 2.

Diagnostic tests for leptospirosis

Management

Patients with suspected or confirmed leptospirosis with mild clinical features and no comorbidities may be managed as outpatients with regular follow up for identification of complications.13 Patients who have clinical features of organ involvement, or those who have comorbidities, must be admitted for in-hospital care. Early initiation of antibiotic treatment is likely to improve outcome.

For mild disease (ie without organ involvement):

  • Administer doxycycline 100 mg twice daily for 7 days.

  • Do the following investigations: complete blood count, C-reactive protein, creatinine, urea, electrolytes, liver transaminases.

  • bilirubin, urine full report.

  • Monitor urine output.

  • Review every 48 hours.

  • Admit to hospital if there is jaundice, reduction in urine output, haematuria, cough, or difficulty breathing, or if clinically very ill.

For those requiring hospital admission:

  • Do the following investigations: complete blood count, C-reactive protein, creatinine, urea, electrolytes, liver transaminases, bilirubin, urine full report, coagulation tests and blood picture (to identify disseminated intravascular coagulopathy), ECG, chest radiograph.

  • Commence intravenous antibiotics: penicillin G 1.5 million units 6 hourly, or ceftriaxone 1 g twice daily for 7 days. For those with penicillin or cephalosporin allergy, doxycycline or a macrolide (azithromycin or clarithromycin) may be used.

  • Monitor fluid intake and urine output.

  • Fluid intake should be guided by clinical assessment of hydration. In adults, the intake should be around 2.0-2.5 L per 24 hours.

  • If oliguric, the daily intake should be equal to the previous day's urine output plus estimated insensible loss (usually around 500 ml). If the previous day's output is not known, the hourly intake should be calculated as the previous hour's urine output plus 25 ml.

  • All nephrotoxic and hepatotoxic drugs should be stopped. Anticoagulants and antiplatelet drugs may need to be stopped if bleeding manifestations are present.

  • Critically ill patients (ie those with haemodynamic instability, respiratory compromise, haemoptysis, reduced consciousness, or other signs of organ dysfunction) will require to be managed in a high dependency unit or intensive care unit.

  • Those requiring intensive care should be managed in accordance with standard critical care management protocols and guidelines.

  • Mechanical ventilatory support may be required, especially in pulmonary haemorrhage and acute respiratory distress syndrome.

  • The use of high dose corticosteroids for treatment of leptospirosis is not supported by high quality evidence, and routine use is not recommended. There are reports of potential adjunctive benefit with high dose corticosteroids in severely ill patients.

  • Plasmapheresis has been used in severe leptospirosis, with some non-randomised trials showing benefit, but the evidence is of low quality.

Supportive care and antibiotics remain the mainstay of management in leptospirosis, and there are as yet no specific therapies which influence outcome.

Prevention

Prevention of leptospirosis is through avoidance of potential exposure to infection, and administration of pharmacological prophylaxis to individuals at high risk. Doxycycline 200 mg weekly, commencing one week prior to exposure, and continued through the period of exposure is recommended. No human vaccine is currently available.

Future directions

There are currently no reliable scoring systems or predictive models to determine which patients with leptospirosis are likely to develop severe disease; this is an area for future research. The pathogenesis of severe leptospirosis is poorly understood, and basic sciences research should focus on identifying biomarkers of severity, and potential therapeutic targets. Further randomised trials to evaluate potentially beneficial interventions which could prevent progression to severe disease are required.14

  • © Royal College of Physicians 2022. All rights reserved.

References

  1. ↵
    1. Levett PN
    . Leptospirosis. Clin Microbiol Rev 2001;14:296–326.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Haake DA
    , Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol 2015;387:65–97.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Costa F
    , Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: A systematic review. PLoS Negl Trop Dis 2015;9:e0003898.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Weil A
    . Ueber einer eigenhuemliche, mit Milztumor, Icterus un Nephritis einhergehende, acute Infektionskrankheit. Deutsch Arch Klin Med 1886;39:109.
    OpenUrl
  5. ↵
    1. Evangelista KV
    , Coburn J. Leptospira as an emerging pathogen: a review of its biology, pathogenesis and host immune responses. Future Microbiol 2010;5:1413–25.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Davies HD
    , Simonsen KA. Leptospira. In: Kliegman RM, ed. Nelson Textbook of Pediatrics, 21 ed. Elsevier, 2020:1601–3.
    OpenUrl
  7. ↵
    1. Agampodi SB
    , Karunarathna D, Jayathilala N, et al. Outbreak of leptospirosis after white-water rafting: sign of a shift from rural to recreational leptospirosis in Sri Lanka? Epidemiol Infect 2014;142:843–6.
    OpenUrlCrossRef
  8. ↵
    1. Felzemburgh RD
    , Ribeiro GS, Costa F, et al. Prospective study of leptospirosis transmission in an urban slum community: role of poor environment in repeated exposures to the Leptospira agent. PLoS Negl Trop Dis 2014;8:e2927.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Adler B
    , de la Pena Moctezuma A. Leptospira and leptospirosis. Vet Microbiol 2010;140:287–96.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Trevejo RT
    , Rigau-Perez JG, Ashford DA, et al. Epidemic leptospirosis associated with pulmonary hemorrhage - Nicaragua, 1995. J Infect Dis 1998;178:1457–63.
    OpenUrlCrossRefPubMed
    1. Turner LH
    . Leptospirosis I. Trans R Soc Trop Med Hyg 1967;61:842–55.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rajapakse S
    , Rodrigo C, Balaji K, Fernando SD. Atypical manifestations of leptospirosis. Trans R Soc Trop Med Hyg 2015;109:294–302.
    OpenUrlCrossRefPubMed
  12. ↵
    Ministry of Health, Nutrition and Indigenous Medicine Sri Lanka. National guidelines on management of leptospirosis. MoH, 2016. www.epid.gov.lk/web/images/pdf/Publication/leptospirosis/lepto_national_guidelines.pdf [Accessed 21 Dcember 2021].
  13. ↵
    1. Rajapakse S
    , Rodrigo C, Handunnetti SM, Fernando SD. Current immunological and molecular tools for leptospirosis: diagnostics, vaccine design, and biomarkers for predicting severity. Ann Clin Microbiol Antimicrob 2015;14:2.
    OpenUrlPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Leptospirosis: clinical aspects
Senaka Rajapakse
Clinical Medicine Jan 2022, 22 (1) 14-17; DOI: 10.7861/clinmed.2021-0784

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Leptospirosis: clinical aspects
Senaka Rajapakse
Clinical Medicine Jan 2022, 22 (1) 14-17; DOI: 10.7861/clinmed.2021-0784
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Key points
    • Introduction
    • History
    • Taxonomy and classification
    • Epidemiology and transmission
    • Clinical manifestations
    • Diagnosis
    • Management
    • Prevention
    • Future directions
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Melioidosis: clinical aspects
  • CME: Tropical medicine (138789): self-assessment questionnaire
Show more CME: Tropical medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2023 by the Royal College of Physicians